Drug Trial Radar · NCT03085810
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)
Last checked: Nov 20, 2026Latest source record: Jan 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,225
Actual
Start
Mar 24, 2017
Primary completion
Apr 27, 2023
Study completion Apr 27, 2023
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Mar 21, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks. The optional shorter infusion substudy will evaluate the safety of a shorter infusion of ocrelizumab in a subgroup of participants with early stage RRMS enrolled in the main MA30143 study. Approximately 700 patients will be enrolled in the substudy, and will receive additional 600 mg ocrelizumab administered in a shorter time frame.
Conditions
- Multiple Sclerosis, Relapsing-Remitting
Interventions
OcrelizumabDrug
Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Onset of Confirmed Disability Progression (CDP) Sustained for at Least 24 Weeks and 48 Weeks as Measured Using Expanded Disability Status Scale (EDSS)Time frame: Baseline up to 4 years
- Percentage of Participants With 24-Week and 48-Week Confirmed Disability Improvement (CDI) During the Year 1 Treatment Period, as Measured Using EDSSTime frame: At Weeks 24 and 48 during Year 1
- Percentage of Participants Event-Free for CDP Sustained for at Least 24 and 48 Weeks at Year 1, as Measured Using EDSSTime frame: Year 1 (Weeks 24 and 48)
- Percentage of Participants With 24-Week and 48-Week CDI During the Year 2 Treatment Period, as Measured Using EDSSTime frame: At Weeks 48, 72 and 96 during Year 2
- Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 2, as Measured Using EDSSTime frame: Year 2 (Weeks 72 and 96)
- Percentage of Participants With 24-Week and 48-Week CDI at Year 4, as Measured Using EDSSTime frame: At Weeks 144, 168 and 192 during Year 4
- Percentage of Participants Event-free for CDP Sustained for at Least 24 and 48 Weeks at Year 4, as Measured Using EDSSTime frame: Year 4 (Weeks 168 and 192)
- Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 1, As Measured Using EDSSTime frame: Year 1 (Week 48)
- Percentage of Participants Who Have Improved, Stable, or Worsened Disability Compared to Baseline at Year 2, As Measured Using EDSSTime frame: Year 2 (Week 96)
- Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 3, As Measured Using EDSSTime frame: Year 3
- Percentage of Participants Who Have Improved, Stable, or Worsened Disability at Year 4, As Measured Using EDSSTime frame: Year 4
- Mean Change From Baseline in EDSS Score at Week 24Time frame: From Baseline to Week 24
- Mean Change From Baseline in EDSS Score at Week 48Time frame: From Baseline to Week 48
- Mean Change From Baseline in EDSS Score at Week 72Time frame: From Baseline to Week 72
- Mean Change From Baseline in EDSS Score at Week 96Time frame: Baseline, Week 96
- Mean Change From Baseline in EDSS Score at Week 120Time frame: Baseline, Week 120
- Mean Change From Baseline in EDSS Score at Week 144Time frame: Baseline, Week 144
- Mean Change From Baseline in EDSS Score at Week 168Time frame: Baseline, Week 168
- Mean Change From Baseline in EDSS Score at Week 192Time frame: Baseline, Week 192
- Percentage of Participants Without Protocol-Defined Event of Disease ActivityTime frame: Baseline up to 4 years
- Percentage of Participants Without RelapseTime frame: Baseline up to 4 years
- Annualized Relapse RateTime frame: Baseline up to 4 years
- Sub Study: Number of Participants With IRRs Occurring During or Within 24 Hours Following the First Infusion After Randomization to the Shorter Infusion SubstudyTime frame: Week 24 through Week 144
Locations
193 sites in 29 countries. Site status is shown where the registry gives one.
University of California Irvine
Irvine, California
Palo Alto Medical Foundation Research Center
Sunnyvale, California
University of Colorado Denver
Aurora, Colorado
Advanced Neurology of Colorado, LLC
Fort Collins, Colorado
KI Health Partners, LLC; New England Institute for Clinical Research
Stamford, Connecticut
Georgetown University Medical Center
Washington D.C., District of Columbia
University of South Florida - Bradenton
Tampa, Florida
Shepherd Center Inc.
Atlanta, Georgia
College Park Family Care Ctr
Overland Park, Kansas
The NeuroMedical Center
Baton Rouge, Louisiana
Maine Medical Center
Scarborough, Maine
University of Maryland Medical Center; Department of Neurology
Baltimore, Maryland
Neurology Center of New England
Foxborough, Massachusetts
Dragonfly Research, LLC
Wellesley, Massachusetts
Minneapolis Clinic of Neurology
Golden Valley, Minnesota
Cleveland Clinic Lou Ruvo; Center for Brain Research
Las Vegas, Nevada
Columbia University Medical Center
New York, New York
Island Neurological Associates, P.C.
Plainview, New York
Neurology Associates PA
Hickory, North Carolina
Wake Forest University Health Sciences
Winston-Salem, North Carolina
Cleveland Clinic Foundation; Cleveland Clinic Cancer Center/I40
Cleveland, Ohio
Neurology Specialists, Inc
Dayton, Ohio
Vanderbilt University Medical Center
Nashville, Tennessee
Kane Hall Barry Neurology
Bedford, Texas
MultiCare Health System Institute for Research and Innovation
Tacoma, Washington
Wheaton Franciscan Healthcare - St. Francis Outpatient Center; Center for Neurological Disorders
Milwaukee, Wisconsin
Centro de Especialidades Neurológicas y Rehabilitación - CENyR
Buenos Aires, Argentina
Hospital Churruca Visca
Buenos Aires, Argentina
Fundacion Rosarina de Neurorehabilitacion
Rosario, Argentina
Brain and Mind Centre
Camperdown, New South Wales, Australia
Liverpool Hospital
Liverpool, New South Wales, Australia
John Hunter Hospital
New Lambton, New South Wales, Australia
Royal North Shore Hospital; Department of Neurology
St Leonards, New South Wales, Australia
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia
Box Hill Hospital; Department of Neurology
Box Hill, Victoria, Australia
Austin Hospital; Department of Neurology
Heidelberg, Victoria, Australia
Royal Melbourne Hospital; Department of Neurology
Parkville, Victoria, Australia
Perron Institute for Neurological and Translational Science
Nedlands, Western Australia, Australia
Medizinische Universität Graz; Universitätsklinik für Neurologie
Graz, Austria
Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie
Innsbruck, Austria
Showing 40 of 193 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.